Lexeo Therapeutics Inc (NASDAQ: LXEO) is -71.49% lower on its value in year-to-date trading and has touched a low of $1.45 and a high of $19.50 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The LXEO stock was last observed hovering at around $4.38 in the last trading session, with the day’s gains setting it 0.07%.
Currently trading at $4.45, the stock is 8.01% and 24.00% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.19 million and changing 1.60% at the moment leaves the stock -18.42% off its SMA200. LXEO registered -32.37% loss for a year compared to 6-month loss of -31.96%. The firm has a 50-day simple moving average (SMA 50) of $3.5888 and a 200-day simple moving average (SMA200) of $5.455.
The stock witnessed a 57.80% gain in the last 1 month and extending the period to 3 months gives it a 51.10%, and is 6.46% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.31% over the week and 10.90% over the month.
Lexeo Therapeutics Inc (LXEO) has around 72 employees, a market worth around $147.72M and $0.00M in sales. Distance from 52-week low is 206.90% and -77.18% from its 52-week high. The company has generated returns on investments over the last 12 months (-115.22%).
The EPS is expected to grow by 14.56% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
118.0 institutions hold shares in Lexeo Therapeutics Inc (LXEO), with institutional investors hold 122.03% of the company’s shares. The shares outstanding are 33.19M, and float is at 22.90M with Short Float at 20.89%. Institutions hold 121.11% of the Float.
The top institutional shareholder in the company is EVENTIDE ASSET MANAGEMENT, LLC with over 3.37 million shares valued at $54.04 million. The investor’s holdings represent 10.2089 of the LXEO Shares outstanding. As of 2024-06-30, the second largest holder is JANUS HENDERSON GROUP PLC with 3.16 million shares valued at $50.73 million to account for 9.5873 of the shares outstanding. The other top investors are ADAGE CAPITAL PARTNERS GP, L.L.C. which holds 2.6 million shares representing 7.8715 and valued at over $41.67 million, while CITADEL ADVISORS LLC holds 7.7529 of the shares totaling 2.56 million with a market value of $41.04 million.
Lexeo Therapeutics Inc (LXEO) Insider Activity
The most recent transaction is an insider sale by Townsend Richard Nolan, the company’s Chief Executive Officer. SEC filings show that Townsend Richard Nolan sold 1,074 shares of the company’s common stock on May 16 ’25 at a price of $2.77 per share for a total of $2979.0. Following the sale, the insider now owns 0.22 million shares.
Lexeo Therapeutics Inc disclosed in a document filed with the SEC on May 16 ’25 that Adler Eric (Chief Medical Officer) sold a total of 585 shares of the company’s common stock. The trade occurred on May 16 ’25 and was made at $2.77 per share for $1623.0. Following the transaction, the insider now directly holds 67681.0 shares of the LXEO stock.
Still, SEC filings show that on May 16 ’25, Robertson Jenny (Chief Legal Officer) disposed off 521 shares at an average price of $2.77 for $1445.0. The insider now directly holds 63,098 shares of Lexeo Therapeutics Inc (LXEO).
